Senores Pharma Q4&FY26 Investor Presentation Released
Senores Pharma released its Q4 & FY26 investor presentation. FY26 Total Income reached ₹664 crore (up 62%), EBITDA ₹199.6 crore (up 96%), and PAT ₹121.5 crore (up 108%). Key strategies include acquisitions and U.S. market entry. Cash flow from operations improved to ₹75 crore.
The announcement provides a comprehensive update on the company's financial performance and strategic initiatives, including significant growth figures and key acquisitions/partnerships, which are material to investors.
The company reported significant year-on-year growth in total income, EBITDA, and PAT, alongside improvements in margins and cash flow from operations. Strategic acquisitions and market entries also indicate positive future prospects.
Senores Pharmaceuticals Limited has released its Investor Presentation for Q4 and FY26, following its earnings conference call. The presentation details the company's financial and operational highlights for the fiscal year ending March 31, 2026.
Key financial achievements for FY26 include a Total Income of ₹664.0 crore, a 62% increase year-on-year, and EBITDA growing by 96% to ₹199.6 crore. Profit After Tax (PAT) saw a significant jump of 108% to ₹121.5 crore. The company also reported improvements in Gross Profit Margin, EBITDA Margin, and PAT Margin.
Operationally, Senores Pharmaceuticals highlighted a strong improvement in Cash Flow from Operations, which stood at ₹75 crore for FY26. The company has a robust product pipeline for regulated markets with 51 approved ANDAs, and a strong growth in its Branded Generics business, which grew by approximately 385% year-on-year.
Strategic initiatives include the acquisition of a 51% stake in Zoraya Pharmaceuticals, LLC, and the completion of Phase 1 of acquiring a 75% stake in Apnar Pharmaceuticals Pvt. Ltd. Furthermore, Senores entered the U.S. Federal Market through a 70% joint venture, Amerisyn, to supply pharmaceuticals to federal, veterans, and defense sectors.
The presentation also covers the company's growth strategies, including launching products with ANDA approval potential in the US, expanding into new regulated and emerging markets, and enhancing capabilities for backward integration into API manufacturing. Senores Pharmaceuticals operates with USFDA-approved facilities in the US and India, catering to both regulated and emerging markets.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.